The University of Michigan Comprehensive Cancer Center (UMCCC) requests renewal of its core grant in support of senior leadership, programs and shared facilities. The Cancer Center was established by the Board of Regents in 1989 to provide a focus for all cancer related activities throughout the University. A core grant to support the UMCCC was initially awarded by the NCI in 1988 and renewed for 5 years in 1991. The Center provides an organizational framework to promote interdisciplinary research through the development of defined clinical, basic science and prevention programs in cancer research, and the development and support of shared resources. There are ten clinical research programs including eight representing coordinated research efforts of cancers of major organ systems: breast, prostate, thorax, brain, gastrointestinal tract, cutaneous leukemia/lymphoma and pediatric tumors. In addition, there are programs in radiation oncology research and radiopharmaceuticals development. The five basic science research programs of the Center included molecular oncology, tumor metastasis and extracellular matrix, tumor immunology, cancer pharmacology, and drug discovery and development. The Center proposes two new programs in carcinogenesis and cancer prevention. Support is requested for 11 shared core facilities, including clinical trials, biostatistics, tissue procurement, tumor imaging, molecular biology and protein chemistry, morphology, flow cytometry, experimental radiation, animal facility, transgenic mouse and vector cores. The Cancer Center senior leadership is composed of the director and five associate directors, including one each for clinical research, clinical affairs, basic science research, for prevention and control research and for administration. The University and the Medical Center have made substantial commitments to the Cancer Center including the construction of a new $88 million facility to house the Center's outpatient clinics and research laboratories. The 285 Cancer Center members receive over $55 million in research and training support. In the nine years since its establishment the UMCCC has had a major impact on cancer research at the University of Michigan.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046592-11S3
Application #
2867530
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Project Start
1988-09-30
Project End
2001-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
11
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Harvey, Innocence; Stephenson, Erin J; Redd, JeAnna R et al. (2018) Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. Endocrinology 159:2275-2287
Schuetze, Scott M; Bolejack, Vanessa; Thomas, Dafydd G et al. (2018) Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol 4:814-820
Wagner, Vivian P; Martins, Manoela D; Martins, Marco A T et al. (2018) Targeting histone deacetylase and NF?B signaling as a novel therapy for Mucoepidermoid Carcinomas. Sci Rep 8:2065
Hosoya, Tomonori; D'Oliveira Albanus, Ricardo; Hensley, John et al. (2018) Global dynamics of stage-specific transcription factor binding during thymocyte development. Sci Rep 8:5605
Schofield, Heather K; Tandon, Manuj; Park, Min-Jung et al. (2018) Pancreatic HIF2? Stabilization Leads to Chronic Pancreatitis and Predisposes to Mucinous Cystic Neoplasm. Cell Mol Gastroenterol Hepatol 5:169-185.e2
Su, Wenmei; Feng, Shumei; Chen, Xiuyuan et al. (2018) Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer. Cancer Res 78:3207-3219
Moody, Rebecca Reed; Lo, Miao-Chia; Meagher, Jennifer L et al. (2018) Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes. J Biol Chem 293:2125-2136
Ma, Vincent T; Boonstra, Philip S; Menghrajani, Kamal et al. (2018) Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics. Clin Lymphoma Myeloma Leuk 18:e201-e210
Collins, Dalis; Fry, Christopher; Moore, Bethany B et al. (2018) Phagocytosis by Fibrocytes as a Mechanism to Decrease Bacterial Burden and Increase Survival in Sepsis. Shock :
Wang, Xuexiang; Dande, Ranadheer R; Yu, Hao et al. (2018) TRPC5 Does Not Cause or Aggravate Glomerular Disease. J Am Soc Nephrol 29:409-415

Showing the most recent 10 out of 1493 publications